

Denosumab linked to severe hypocalcemia in dialysis-dependent seniors

January 25 2024, by Elana Gotkine



For female dialysis-dependent patients aged 65 years or older treated for osteoporosis, denosumab is associated with an increased incidence of severe or very severe hypocalcemia, according to a study published online Jan. 19 in the *Journal of the American Medical Association*.

Steven T. Bird, Ph.D., Pharm.D., from the U.S. Food and Drug Administration in Silver Spring, Maryland, and colleagues examined the incidence and comparative risk for severe hypocalcemia with [denosumab](#) versus oral bisphosphonates in a retrospective cohort study involving female [dialysis](#)-dependent Medicare patients aged 65 years or older treated for [osteoporosis](#). The main outcomes were severe hypocalcemia, defined as total albumin-corrected serum calcium

Citation: Denosumab linked to severe hypocalcemia in dialysis-dependent seniors (2024, January 25) retrieved 8 May 2024 from <https://medicalxpress.com/news/2024-01-denosumab-linked-severe-hypocalcemia-dialysis.html>

<p>This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.</p>
--